Karyopharm Therapeutics, Inc. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 10 of 10 Posts
JPMorgan Upgrades Karyopharm After Doctor Survey, Doubles Price Target
Article By: The Fly Tuesday, July 23, 2019 9:17 AM EST
JPMorgan analyst Eric Joseph upgraded Karyopharm Therapeutics to Overweight from Neutral and doubled his price target for the shares to $16 from $8.
In this article: KPTI
Read
Wedbush Boosts Karyopharm Target To $11 From $6 On Xpovio Approval
Article By: The Fly Friday, July 5, 2019 9:50 AM EST
Wedbush analyst David Nierengarten raised his price target for Karyopharm Therapeutics to $11 from $6 after the FDA on Wednesday approved selinexor, now branded as Xpovio.
In this article: KPTI
Read
Karyopharm Drops 40% After FDA Posts Selinexor Meeting Briefing Docs
Article By: The Fly Friday, February 22, 2019 2:49 PM EST
Shares of Karyopharm are moving sharply lower after the FDA posted briefing documents for the Oncologic Drugs Advisory Committee Meeting planned for February 26 to review the New Drug Application for Selinexor.
In this article: KPTI
Read
Stocks For You To Swing-Trade: KPTI, SPR, LNG
Article By: Ryan Mallory Friday, July 20, 2018 5:56 AM EST
Take a look at three trading ideas to prep you for the next trading session.
In this article: SPR, LNG, KPTI
Read
Week In Review: Grail, An Oncology Diagnostics Company, Taps China Investors For $300 Million
Article By: ChinaBio® Today Saturday, May 26, 2018 4:42 PM EST
Grail, a Hong Kong-US oncology diagnostics company, announced a $300 million C financing. The company is sequencing large populations of people -- some with cancer, some without -- to discover an early blood-based diagnostic test for cancer.
In this article: ILMN, KPTI
Read
Syros Pharmaceuticals: Despite High-Demand Treatments, We Remain Cautious
Article By: Don Dion Wednesday, July 6, 2016 9:17 PM EST
Based in Watertown, Massachusetts, Syros Pharmaceuticals is a biopharmaceutical company that is developing treatments to control genes in patients with cancer, immune-mediated diseases, and other illnesses.
In this article: NVS, AGIO, KPTI, SYRS
Read
Seven Biotech Names On The Upswing: 2016 Small-Cap Biotech Watchlist Update
Article By: The Life Sciences Report Wednesday, March 9, 2016 5:47 PM EST
Biotech stocks—and the stock market in general—took a dive at the beginning of 2016, headed down on macroeconomic factors such as financial instability in China.
In this article: SGYP, CRMD, ORMP, SRNE, ARRY, PTIE, AGEN, GALE, PPHM, EVOK, ADMA, AKBA, KPTI, VSTM, AST, RXDX, AGTC, WVE, FATE, FLKS, PIRS, ABEO
Read
Insider Trading Report Edition 251: Notable Buys And Sales
Article By: Asif Suria Sunday, April 12, 2015 10:42 PM EST
Insider buying decreased last week with insiders buying $36.59 million of stock compared to $38.72 million in the week prior. Selling also declined slightly with insiders selling $1.08 billion of stock last week compared to $1.09 billion in the week prior.
In this article: AGCO, LUB, DRI, OPK, KPTI, ANTM, GIII, TOL, SIX
Read
Rayno Life Science Small Cap Picks: CLDX, PACB, FMI…Update-1
Article By: Rod Raynovich Monday, November 17, 2014 12:00 PM EST
Recent small cap picks.
In this article: ALXN, CLDX, GHDX, ILMN, REGN, SGEN, ALKS, GILD, PACB, KPTI, FMI, FCSC
Read
ASH 2014 Abstracts Are About To Hit: Here Are Some Of The Names To Follow
Article By: Jake King Thursday, November 6, 2014 8:30 AM EST
One of the biggest events in healthcare annually, the American Society of Hematology’s annual meeting (56th!) begins on December 6, but abstracts from the conference will be released this morning. Here's a primer on the stocks to watch.
In this article: BMY, MRK, GERN, TGTX, EPZM, AGIO, KPTI, KITE, BLUE
Read
1 to 10 of 10 Posts